Patent Rebuff For Roche’s Valcyte In India, Again
Executive Summary
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.
You may also be interested in...
Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.
India dismisses patent on Roche's Valcyte
India has set aside a patent on Roche's Valcyte (valganciclovir) used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.